5Bick RL. Cancer-associated thrombosis[J]. N Eng J Med, 2003, 349(2): 109-111.
6Letai A, Kuter DJ. Cancer, coagulation, and anticoagulation[J]. Oncologist, 1999, 4(6): 443--449.
7Pruemer J. Prevalence, causes, and impact of cancer-associated thrombosis[]]. AmJ Health Syst Pharm, 2005, 62(22 Suppl 5): s4--s6.
8Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data[J]. Medicine, 1999, 78(5): 285-291.
9Burris HA. Low-molecular-weight heparins in the treatment of cancer-associated thrombosis: a new standard of care[J]? Semin Oncol, 2006, 33(2 Suppl 4):S3-S16; quiz S41-S42.
10BaronJA, Gridley G, Weiderpass E, et al. Venous thromboembolism and cancer[J]. Lancet, 1998, 351(9109): 1077-1080.
8GROVE J R, PEVEC W C. Venous thrombosis related to peripher- ally inserted central catheters[J]. J Vasc Interv Radiol, 2000, 11 (7) : 837 -840.
9CORTELEZZIA A, FRACCHIOLLA N S, MAISONNEUVE P, et al. Central venous catheter - related complications in patients with hematological malignancies: a retrospective analysis of risk factors and prophylactic measures[ J]. Leuk Lymphuma, 2003, 44 (9) : 1495 - 1501.
10PRADONI P, POLISTENA P, BENARDI E, et at. Upper - ex- tremity deep vein thrombosis: risk factors, diagnosis, and compli- cations [J]. Arch Intern Med, 1997, 157 (1) : 57 -62.
